In a significant development in the global fight against dengue fever, Japanese pharmaceutical company Takeda has forged a strategic partnership with Hyderabad-based firm Biological E Ltd. The collaboration aims to manufacture Takeda’s dengue vaccine, known as TAK-003.
Strengthening Dengue Vaccine Manufacturing Capabilities
The joint effort between Takeda and Biological E represents a crucial step toward achieving the World Health Organization’s ambitious goal of zero case-fatality rate due to dengue by 2030. Dengue, a mosquito-borne viral disease, poses a substantial public health threat worldwide. Approximately half of the world’s population is now at risk of contracting dengue, with India and Southeast Asia being highly endemic regions.
Biological E, a leading vaccines and biologics company, will scale up its production capacity to potentially reach 50 million doses annually. This expansion will significantly contribute to Takeda’s efforts to manufacture 100 million doses annually within the decade. The partnership aims to ensure a sustainable global supply of the dengue vaccine.
TAK-003: A Multi-Dose Vial for Dengue Prevention
TAK-003, developed by Takeda, is a promising vaccine designed to combat dengue. By increasing manufacturing capacity for multi-dose vials, the collaboration will drive sustainable access in more endemic countries. The vaccine’s efficacy and safety profile make it a critical tool in controlling the spread of dengue.
Mr. Gary Dubin, President of Takeda’s Global Vaccine Business Unit, expressed pride in the strategic partnership. He stated, “We are proud to announce a strategic manufacturing partnership with Biological E Ltd, which has deep expertise in vaccine manufacturing and longstanding support of public health programs around the world.”
Hyderabad: The Hub for Dengue Vaccine Production
Telangana Chief Minister Anumula Revanth Reddy announced that Hyderabad will host the facility where the dengue vaccine, a result of the Takeda-Biological E partnership, will be manufactured. This collaboration underscores India’s role in advancing global health initiatives.
As the world grapples with infectious diseases, such partnerships exemplify the power of international cooperation and scientific innovation. The Takeda-Biological E alliance holds the promise of protecting millions of lives from dengue, marking a significant milestone in the ongoing battle against this formidable disease.
